Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602
about
Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccineShigella Diversity and Changing Landscape: Insights for the Twenty-First CenturyA multicentre study of Shigella diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiologyImmunology of Gut Mucosal VaccinesImmunoproteome analysis of soluble and membrane proteins of Shigella flexneri 2457T.A genome-scale proteomic screen identifies a role for DnaK in chaperoning of polar autotransporters in Shigella.A changing picture of shigellosis in southern Vietnam: shifting species dominance, antimicrobial susceptibility and clinical presentationVirulence, inflammatory potential, and adaptive immunity induced by Shigella flexneri msbB mutantsConstruction and characterization of bivalent Shigella flexneri 2a vaccine strains SC608(pCFAI) and SC608(pCFAI/LTB) that express antigens from enterotoxigenic Escherichia coli.Attenuated Shigella flexneri 2a vaccine strain CVD 1204 expressing colonization factor antigen I and mutant heat-labile enterotoxin of enterotoxigenic Escherichia coli.Virulence factors associated with pediatric shigellosis in Brazilian Amazon.A piglet model of acute gastroenteritis induced by Shigella dysenteriae Type 1Polar targeting of Shigella virulence factor IcsA in Enterobacteriacae and VibrioThe immune responses to bacterial antigens encountered in vivo at mucosal surfaces.Outer membrane protein A (OmpA) of Shigella flexneri 2a, induces protective immune response in a mouse model.Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans.Parameters underlying successful protection with live attenuated mutants in experimental shigellosisSafety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults.Predominance of serotype-specific mucosal antibody response in Shigella flexneri-infected humans living in an area of endemicity.Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adultsCommunity-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteersShigella isolates from the global enteric multicenter study inform vaccine development.Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity.Live attenuated S. Typhimurium vaccine with improved safety in immuno-compromised mice.Differential response of the cynomolgus macaque gut microbiota to Shigella infectionBacterial infectious disease control by vaccine development.Targeting cancer's weaknesses (not its strengths): Therapeutic strategies suggested by the atavistic modelShigella flexneri 3a outer membrane protein C epitope is recognized by human umbilical cord sera and associated with protective activityAnalysis of virulence and inflammatory potential of Shigella flexneri purine biosynthesis mutantsPrevention and self-treatment of traveler's diarrhea.Shigella outer membrane protein PSSP-1 is broadly protective against Shigella infection.Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni.Enteric pathogens as vaccine vectors for foreign antigen deliveryEvaluation of the Safety, Tolerability, and Immunogenicity of an Oral, Inactivated Whole-Cell Shigella flexneri 2a Vaccine in Healthy Adult Subjects.Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.Type III secretion systems and disease.Establishment of a Shigella sonnei human challenge model in Thailand.Progress and pitfalls in Shigella vaccine research.Changing trends and serotype distribution of Shigella species in Beijing from 1994 to 2010Finding Potential Therapeutic Targets against Shigella flexneri through Proteome Exploration
P2860
Q21245322-5DEB5586-C92C-4306-AAA7-3792D1B1EDD9Q26752367-3329EC5D-54D1-4632-934F-CB00F9169A47Q28767862-492BB4EA-7665-47CA-AC9A-D78BEBE9C78BQ28972559-FE682855-995B-4E2A-9132-E72D388E87E2Q33262196-43DCB573-210E-48A8-8177-EE4040F978D7Q33493807-B2A5E9FC-9D9E-4102-8E53-2858AAE4349FQ33518017-98D8EA93-11C9-4671-BA2E-8471A04C0179Q33557800-324E8791-3633-4E40-8385-04389D1D30CAQ33558374-CFF228A0-4F8C-466E-AF83-593F90EA33FAQ33597022-96114964-74F8-4FE9-B72B-C6D91D9DCFD1Q33608925-72F3A6F3-DD95-4D9E-AE8D-1C78E9C2E9BDQ33678906-BC8B99DC-A554-4207-B12A-2488F82F1AF7Q33934139-F0F33E6A-7260-412C-9F14-207CD484A702Q33955531-12AC2A4D-DF20-4366-BFA5-6234F2031E32Q33983350-D3F48233-15CE-4E4F-AD37-C08015A89CC4Q34003433-3569BCAF-7FE4-4A46-ACEB-D1E57512B5AEQ34006071-7314C482-BB04-4170-B574-D1019B217753Q34008338-4F149F42-1097-488A-AFCD-74ADA62E44BCQ34008763-5D1BE0EE-409A-437F-8C76-0BB70A168C2FQ34120926-321B7323-0732-4A33-AB1E-2F5C159FE8F9Q34194587-FE4F4844-44EB-4352-90C3-ECB3B6DE7DA4Q34202171-FA062FBA-37B5-485E-A7A3-423519BC0151Q34394744-D1CC34F0-502F-4601-905E-B150D52ED1A0Q34429033-01E86ED0-3291-4C6C-9FB8-D2D4D7FCB026Q34765669-D45A07ED-0607-4E86-9A88-A099FC470D61Q34785982-A602EB20-5063-41B5-9417-36B5FB3D5C89Q34807615-56D94621-C501-4D92-8AFD-1C9E691C85B2Q34935297-899544EA-D631-43AB-8D98-8EF8E7F242CCQ34941041-CD6FC8DE-AD13-4401-B501-E4C57043C7D3Q34974972-42F6FF6C-DE0D-40F1-B014-12499408E452Q35221181-B555E926-7F15-4627-936E-37F418F50D65Q35887055-6393821B-E211-4768-95F2-9FE71198D7F4Q35896020-740E0CA6-D46A-47F4-8307-88D604289FFAQ36764372-58900109-4C15-4536-8842-40AD749045DFQ36844719-B59C768B-AA42-4008-A82A-A2E5D0E7E9AEQ36969851-0F29C6CA-5298-4149-9080-7F40C048BC5CQ37066116-8A910213-8CCC-46C8-91B6-141390DA11CEQ37105553-6CD1CE14-EF31-4BE0-8EEF-350F355D0250Q37113756-3424E79B-0E8D-437F-B5B9-6B0B835BAE0DQ37427534-EF317BB8-0B00-4779-A5F1-163F96C251C8
P2860
Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602
description
1999 nî lūn-bûn
@nan
1999 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602
@ast
Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602
@en
type
label
Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602
@ast
Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602
@en
prefLabel
Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602
@ast
Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602
@en
P2093
P2860
P1476
Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602
@en
P2093
A B Hartman
A Fontaine-Thompson
L L VanDeVerg
M M Venkatesan
P J Sansonetti
P2860
P304
P407
P577
1999-07-01T00:00:00Z